Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Angiotensin II Receptor Blockers (ARBs) Market Estimated to Flourish by 2026

Author: Akash Pande
by Akash Pande
Posted: Jan 10, 2019

Angiotensin II receptor blockers (ARBs) helps in blocking angiotensin II action, allowing the blood vessels to dilate. Angiotensin II are chemicals in the human body that affect the heart by narrowing down the blood vessels, not allowing the required space to the blood to move, resulting in increasing blood pressure, known as hypertension, and cardiovascular risks. Leading brands in the ARB market include Benicar (olmesartan medoxomil), Diovan (valsartan), Micardis (telmisartan), Cozaar (Osartan), Edarbi (Azilsartan), Atacand (candesartan), Teveten (eprosartan), and Avapro (irbesartan). ARBs help in the treatment of conditions, such as, high blood pressure, heart failure, chronic kidney diseases, and kidney failure in diabetes. Hypertension and cardiovascular risks are interrelated. Increase in blood pressure can cause high cardiovascular risk in patients. According to the World health Organization, blood pressure is the most prevalent cause of heart failure, resulting in increasing mortality rates. ARBs are available in generic and under specialty brands also. ARBs are a popular choice for treating high blood pressure and are usually recommended to the patients under 55 years of age. Clinical studies have proved that the side effects of ARBs are negligible; besides, ARBs are comparatively inexpensive. Increase in the availability of generic ARBs has created various options for the patient population.

ARB drugs are found to have least number of side effects in patients / users, which in turn increases its demand and hence is more preferred than other hypertension drugs. ARBs are gaining popularity as they have the capability of improving the quality of life of the patients. Unlike ACEIs (Angiotensin converting enzyme inhibitors), ARMs do not cause cough or danger of swelling of the lips, throat, or tongue. Moreover, growth in patient population is augmenting the market for ARBs drugs. These drugs are generally preferred over other drugs, as certain studies have suggested that AMBs are also effective in preventing stroke and dementia. Loss of exclusivity leading to increased generic competition, is major restraint for growth of angiotensin II receptor blockers (ARBs) market. Furthermore, compared to ARBs, ACIEs have special advantage for patients with diabetic nephropathy and those suffering from chronic kidney diseases, resulting in dysfunction of kidneys. Moreover, patent expiry of antihypertensive drugs, such as, Benicar and Diovan hinders the growth of the angiotensin II receptor blockers (ARBs) market. In 2018, FDA recalled the list of valsartan drugs as it is linked to cancer, and is anticipated to affect the angiotensin II receptor blockers (ARBs) market. Increasing cases of hypertension, heart failure, obesity, unhealthy lifestyle choices are boosting the demand for ARBs. However, growing commercial availability of ARBs as a generic medicine is leading to adverse effects in patients, resulting in hospitalization or consultation.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52416

The global angiotensin II receptor blockers (ARBs) market can be segmented on the basis of region, application, and distribution channel. Based on the application, ARBs are used majorly in the treatment of hypertension, cardiovascular risks, and others. In terms of distribution channel, the market caters to hospital pharmacies, online pharmacies, and retail pharmacies. Based on region, the global angiotensin II receptor blockers (ARBs) market has been studied across North America, Europe, Asia Pacific, the Middle East, and Latin America. North America dominates the global angiotensin II receptor blockers (ARBs) market due to availability of accurate treatment options, advanced health care infrastructure, and early diagnosis process. Increasing obesity rate in North America is also one of the reasons for the dominance of the region on the global market, followed by Europe and Asia Pacific.

Leading players operating in the global angiotensin II receptor blockers (ARBs) market include Daichii Sankyo, Lupin, Novartis, Abbvie, Takeda, AstraZeneca, and Zydus Cadila.

Request to View ToC of the report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=52416

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

About the Author

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materia

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Akash Pande

Akash Pande

Flag of India
India

Member since: Jan 03, 2019
Total live articles: 297

Related Articles